AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00060346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
Study NCT00060346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes.
Study NCT00060346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.
Study NCT00060346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Study NCT00060346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions.
Study NCT00957008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group weight loss program
Description: Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
Study NCT00957008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group weight loss program plus use of the Senseware Armband
Description: Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
Study NCT00957008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the senseware armband alone program
Description: Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
Study NCT03530371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
Study NCT04775329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: Rifaximin 1000mg OM
Study NCT04672759 — intervention group
Intervention type: DRUG
Intervention: Durvalumab
Description: Patients receive durvalumab as an intravenous infusion over 60 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
Study NCT04672759 — intervention group
Intervention type: DRUG
Intervention: Durvalumab
Description: Durvalumab monotherapy or combined with chemotherapy and/or radiotherapy.
Study NCT01849302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverages varying in macronutrient content on appetite
Description: In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
Study NCT01423799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional supplements containing arginine, n-3 and nucleotides
Description: Nutritional intervention with immuno-nutrients
Study NCT01423799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric control
Description: Isocaloric and isonitrogenous control without immuno nutrients
Study NCT00264875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 75mg BID, titrated up to 300mg according to individual response and tolerability
Study NCT02368054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infiltration anesthesia
Study NCT02368054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: Infiltration anesthesia
Study NCT04674592 — intervention group
Intervention type: OTHER
Intervention: Blood samples and biopsies
Description: Blood samples for analysis of biomarkers of muscle damage. Muscle biopsies for histological analysis of muscle damage.
Study NCT05373147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αPD1-MSLN-CAR T cells
Description: The safety and efficacy of αPD1-MSLN-CAR T cells will be assessed in a standard 3+3 dose escalation approach. Four doses of CAR T cells will be evaluated in this study: 1×10\^5 CAR+ T cells/kg, 3×10\^5 CAR+ T cells/kg, 1×10\^6 CAR+ T cells/kg, and 3×10\^6 CAR+ T cells/kg.
Study NCT00662103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise intervention
Description: Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months.
Study NCT00662103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health \& Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
Study NCT00662103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
Study NCT00662103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Administered at measured at baseline, 3, 6, 12, and 18 months
Study NCT00662103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: assessment of therapy complications
Description: Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
Study NCT00662103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fatigue assessment and management
Description: The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
Study NCT00662103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
Study NCT00662103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Description: We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing
Description: Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing + adhesive
Description: Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips (parallel)
Description: Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips (perpend)
Description: Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips + benzoin
Description: Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
Study NCT03375190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Dressing + adhesive + strips + spray
Description: Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
Study NCT01445028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin 20mg daily for 12 weeks
Study NCT04655664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: not currently consumed vitamin D supplements regularly
Description: The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
Study NCT04655664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: consumed vitamin D supplements regularly
Description: The tests carried out were examination of 25 (OH) D and 1.25 (OH) D levels of serum and saliva, examination of demographic data, and other anthropometries. The examination was carried out by taking 5 mL of blood and 2 mL of saliva, and then checking the serum and saliva levels of 25 (OH) D and 1.25 (OH) D. Before the examination, the research subjects were asked not to consume food or drink for at least 90 minutes before being examined. Centrifugation was carried out (2500 g, 10 minutes) and the product immediately stored at -20 oC. In the serum examination, after the blood was drawn, centrifugation was carried out and the product stored at -20 oC for further determination of the levels of 25 (OH) D and 1.25 (OH) saliva.
Study NCT02705638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
Study NCT02705638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
Study NCT01550497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised spinal stabilization exercises
Description: Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
Study NCT03224273 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proximal box inlay retained bridge
Description: inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
Study NCT03224273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal box inlay retained bridge
Description: inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
Study NCT02575521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol-Dexmedetomidine group
Description: Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
Study NCT02575521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane group
Description: Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
Study NCT02001233 — intervention group
Intervention type: BIOLOGICAL
Intervention: EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
Study NCT05101603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Abrasive
Description: Applied with Nd:YAG Laser on periodontal pockets
Study NCT05101603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Applied with Air Abrasive on periodontal pockets
Study NCT05101603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non surgical periodontal therapy
Description: The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
Study NCT05101603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical periodontal therapy
Description: The first phase, in which optimum plaque control is achieved and local etiological factors are removed, is the first step of all periodontal diseases and surgical procedures.
Study NCT01169077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
Study NCT01169077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EP-1300
Description: Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
Study NCT02559466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS - ) - MagPro®
Description: Class IIa
Study NCT02559466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS - ) - MagPro®
Description: Class IIa
Study NCT02559466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positon Emission Tomography (PET) - Discovery 710®
Description: Class IB
Study NCT02559466 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Positon Emission Tomography (PET) - Discovery 710®
Description: Class IB
Study NCT04993378 — intervention group
Intervention type: DEVICE
Intervention: EV-array
Description: Collect peripheral blood sample of 40 gastric cancer patients pre-treatment. Blood samples will be transferred to central lab to detect EV-score by EV-array. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST.~Clinical data, including tumor stage, metastastic organ, regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
Study NCT01200901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: quetiapine XR 100 - 300 mg (flexible dosing)
Study NCT01654510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Group
Description: This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
Study NCT01654510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vocational Services as Usual
Study NCT01339546 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02995616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regular therapy settings
Description: Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
Study NCT02995616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 100% guidance force
Description: Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
Study NCT02995616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 60% guidance force
Description: Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
Study NCT02549768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
Study NCT02549768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
Study NCT02326558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic microwave ablation-assisted enucleation
Study NCT02326558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic partial nephrectomy
Study NCT01134965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin plus Digoxin
Description: Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
Study NCT01134965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5 mg as single dose
Study NCT01240460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL765 (SAR245409)
Description: Supplied as 10-mg and/or 50-mg capsules
Study NCT01240460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Supplied as 100-mg, 150-mg and/or 200-mg tablets
Study NCT02811692 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT03344003 — intervention group
Intervention type: DRUG
Intervention: Wilate or Nuwiq
Description: Wilate or Nuwiq administered via intravenous injection